SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13D
(Rule 13d-101)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO
RULE 13d-2(a)
(Amendment No. 16) ¹
Xerox Corporation
(Name of Issuer)
Common Stock, \$1 par value
(Title of Class of Securities)
<u>984121 60 8</u>
(CUSIP Number)

XEROX CORP Form SC 13D/A March 18, 2019

NAME OF REPORTING PERSONS

1

Darwin Deason CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* 2 (a) " (b) " SEC USE ONLY 3 SOURCE OF FUNDS 4 OO (see Item 3 to the Original Schedule 13D) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED URSUANT TO ITEM 2(d) OR 2(e) 5 CITIZENSHIP OR PLACE OF **ORGANIZATION** 6 USA **SOLE VOTING POWER** 7 15,322,341* SHARED VOTING POWER NUMBER OF **SHARES** BENEFICIALLY -0-OWNED BY 9 SOLE DISPOSITIVE POWER **EACH REPORTING**

PERSON WITH 15,322,341*

10SHARED DISPOSITIVE POWER

-0-

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

11

15,322,341*

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW

(11) EXCLUDES CERTAIN

SHARES

12

..

PERCENT OF CLASS

REPRESENTED BY AMOUNT IN

ROW (11)

13

6.7%*

TYPE OF REPORTING PERSON

14

IN

^{*} Includes 6,741,572 Shares issuable upon the conversion of 180,000 shares of Xerox Series B Preferred Stock.

This amendment No. 16 to Schedule 13D relates to the Schedule 13D filed on January 17, 2018 (the "Original Schedule 13D") by the Reporting Person ("Amendment No. 16"). Capitalized terms used but not defined in this Amendment No. 16 shall have the meanings set forth in the Original Schedule 13D.

Item 4.

Purpose of Transaction.

Item 4 is hereby amended to add the following:

On March 15, 2019, the Issuer and Mr. Deason entered into a letter agreement (the "Waiver Letter"), pursuant to which Mr. Deason, in his capacity as the holder of all of the issued and outstanding shares of Xerox Series B Preferred Stock, waived certain provisions of the Issuer's certificate of incorporation and consented to the Issuer's proposed holding company reorganization.

The foregoing description of the Waiver Letter and the waiver and consent contemplated thereby is not complete and is subject to and qualified in its entirety by reference to Exhibit 99.1, the terms of which are incorporated by reference herein.

Item 5.

Interest in Securities of the Issuer.

Items 5(a)-(c) are hereby amended and restated to read as follows:

As of the date hereof, the Reporting Person may be deemed to beneficially own, in the aggregate, 15,322,341 Shares, including 6,741,572 Shares issuable upon the conversion of 180,000 shares of Xerox Series B Convertible Perpetual Preferred Stock, par value \$1.00 per share, representing approximately 6.7% of the Issuer's outstanding Shares (based upon the 229,726,488 Shares stated to be outstanding as of January 31, 2019 by the Issuer in the Issuer's Annual Report on Form 10-K for the fiscal year ended December 31, 2018, filed with the Securities and Exchange Commission on February 25, 2019).

A.Mr. Deason

Mr. Deason beneficially owns 15,322,341 Shares, including 6,741,572 Shares issuable upon the conversion of 180,000 shares of Xerox Series B Preferred Stock.

Percentage: Approximately 6.7%

- 1. Sole power to vote or direct vote: 15,322,341
- (b) 2. Shared power to vote or direct vote: 0
 - 3. Sole power to dispose or direct the disposition: 15,322,341
 - 4. Shared power to dispose or direct the disposition: 0

(c) Mr. Deason has not entered into any transactions in the Shares or shares of Xerox Series B Preferred Stock during the last sixty days.

The filing of this Schedule 13D shall not be deemed an admission that the Reporting Person is, for purposes of Section 13(d) of the Act, the beneficial owners of any securities of the Issuer that he does not directly own. The Reporting Person specifically disclaims beneficial ownership of the securities reported herein that he does not directly own.

Item 6.	Contracts, Arrangemen	ts, Understandin	gs or Relationship	s With Res	pect to	Securities	of o	the Issuer.

Item 6 is hereby amended to add the following:

The disclosure set forth above in Item 4 is incorporated herein by reference.

Item 7.

Material to be Filed as Exhibits.

Item

7 is hereby amended to add the following exhibit:

99.1 Waiver Letter (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by the Issuer on March 18, 2019).

SIGNATURES

After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: March 18, 2019

By:/s/ Darwin Deason Darwin Deason